Biocon (NSE:BIOCON) Other Current Payables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BIOCON Biocon Ltd NSE:BIOCON
89 GF Score
Price ₹417.00
GF Value ₹332.20
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Biocon Other Current Payables?

Biocon NSE:BIOCON -0.71% 89 Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:BIOCON with a GF Score™ of 89/100 and a GF Value™ of ₹332.20 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Biocon's Other Current Payables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Biocon's quarterly Other Current Payables increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹9,667 Mil) but then declined from Mar. 2026 (₹9,667 Mil) to Jun. 2026 (₹0 Mil).

Biocon's annual Other Current Payables increased from Mar. 2024 (₹7,863 Mil) to Mar. 2025 (₹9,326 Mil) and increased from Mar. 2025 (₹9,326 Mil) to Mar. 2026 (₹9,667 Mil).

Biocon Other Current Payables Related Terms

Biocon Other Current Payables Historical Data

* Premium members only.

The historical data trend for Biocon's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocon Other Current Payables Chart

Biocon Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,630.00 4,065.00 7,863.00 9,326.00 9,667.00

Biocon Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 9,667.00 0.00
NSE:BIOCON
89GF Score
Biocon Ltd NSE:BIOCON
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocon Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0 Mil mean?
Biocon (NSE:BIOCON) has a Other Current Payables of ₹0 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biocon and its competitors.
Is Biocon's Other Current Payables too high?
Biocon's current Other Current Payables is ₹0 Mil. Overall, Biocon has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Other Current Payables compare to VRTX and REGN?
Biocon's Other Current Payables of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biocon and its competitors. Biocon's current Other Current Payables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹332.20, compared to a current price of ₹417.00 — trading 25.5% above its estimated fair value. The current Other Current Payables is ₹0 Mil. Biocon's overall GF Score™ is 89/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocon (NSE:BIOCON) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹417.00 is trading 25.5% above its estimated GF Value™ of ₹332.20. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for NSE:BIOCON:

  • Other Current Payables: ₹0 Mil
  • GF Value™: ₹332.20 vs. price of ₹417.00 (25.5% above fair value)
  • GF Score™: 89/100 with 9 warning signs

No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocon Business Description

Other Exchanges 532523:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score

Get the complete analysis for NSE:BIOCON

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹417.00
Price
₹332.20
GF Value